Levetiracetam Induced Steven Johnson Syndrome with Acute Kidney Injury

Levetiracetam is a newer anti-epileptic drug and has a novel mechanism of action, that is modulation of synaptic neuro-transmitter release. Due to its good oral tolerability, wide therapeutic range and minimal systemic adverse effects, it is gaining popularity in a wide spectrum of seizure disorders. Cutaneous adverse effects are uncommon with levetiracetam, with sparse reports of reversible maculopapular rashes, Steven-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN) and Drug Reaction with Eosinophilia Syndrome (DRESS). Previously, cases of Levetiracetam induced SJS have been reported, but none in association with severe renal dysfunction. Here we report a patient who developed SJS associated with acute kidney injury, secondary to levetiracetam, which recovered spontaneously after stopping the drug.

[1]  E. Ramírez,et al.  Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study , 2018, European Journal of Clinical Pharmacology.

[2]  S. Rüegg,et al.  The risk of Stevens‐Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs , 2017, Epilepsia.

[3]  N. Mehra,et al.  Spectrum of Cutaneous Adverse Reactions to Levetiracetam and Human Leukocyte Antigen Typing in North-Indian Patients , 2016, Journal of epilepsy research.

[4]  M. Plaisance,et al.  Levetiracetam-Associated Acute Kidney Injury and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome , 2014 .

[5]  C. Ng,et al.  HLA‐B*15:02 association with carbamazepine‐induced Stevens‐Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled‐data analysis and meta‐analysis , 2014, Epilepsia.

[6]  G. Montouris,et al.  Levetiracetam as a possible contributor to acute kidney injury. , 2014, Clinical therapeutics.

[7]  Xiao-feng Li,et al.  Stevens–Johnson syndrome induced by levetiracetam , 2012, Seizure.

[8]  C. Pedrós,et al.  Levetiracetam-Induced Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome , 2012, The Annals of pharmacotherapy.

[9]  R. Calabró,et al.  Levetiracetam-associated loss of libido and anhedonia , 2012, Epilepsy & Behavior.

[10]  A. Makris,et al.  Levetiracetam-induced severe acute granulomatous interstitial nephritis , 2012, Clinical kidney journal.

[11]  S. Kesari,et al.  Levetiracetam-induced interstitial nephritis in a patient with glioma , 2012, Journal of Clinical Neuroscience.

[12]  T. Beswick,et al.  Dose-related levetiracetam-induced reticulated drug eruption. , 2010, Journal of drugs in dermatology : JDD.

[13]  E. Ingulli,et al.  Levetiracetam induced interstitial nephritis and renal failure. , 2009, Pediatric neurology.

[14]  E. Ben-Menachem,et al.  Efficacy and Tolerability of Levetiracetam 3000 mg/d in Patients with Refractory Partial Seizures: A Multicenter, Double‐Blind, Responder‐Selected Study Evaluating Monotherapy , 2000, Epilepsia.

[15]  P. Wolkenstein,et al.  Levetiracetam: a possible new inducer of toxic epidermal necrolysis and Stevens-Johnson syndrome in 2 cases. , 2013, JAMA dermatology.

[16]  E. Ben-Menachem,et al.  Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. , 2000, Epilepsia.